Assessment 2: A Right to Experimental Drugs? Capella University PHI FPX3200 Ethics in Health Care

Ethical Theories Here, the natural law perspective is solely concerned with the patient. However, given the variety of circumstances that might affect a patient's response to treatment, it is very likely that an experimental medicine that works for one patient may not work the same for another. Those who disagree with this assertion, though, offer five justifications for why patients who are terminally sick should be given experimental medications. First, they contend that the majority of individuals who are terminally sick do not participate in clinical studies. According to them, even if the medicine is ultimately authorized, people who have a limited period of time to live will not be able to take it when the clinical trials are over. In addition, the FDA's medicine approval procedure takes too long. Last but not least, patients should have the freedom to try to extend their lives without having to rely on the federal government (Flanagan & Hannikainen, 2020). Moral Principles Critics contend that the FDA approach is preferable since drug approval is essential and will result in the betterment of more people. They think that when the FDA has less oversight, safety precautions may be compromised and there may be a risk of inaccurate information being spread about a new drug. The first viewpoint, however, has greater merit because patients ought to have the freedom to make their own decisions. Healthcare providers must be truthful and straightforward in order for the four ethics to remain uninformed. Healthcare providers should support the right-to-try path where it is possible that an